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trials with multiple arms: a systematic review
Gabriel Baron1,2,3*, Elodie Perrodeau1,2,3, Isabelle Boutron1,2,3,4 and Philippe Ravaud1,2,3,4,5Abstract
Background: Multiple-arm randomized trials can be more complex in their design, data analysis, and result
reporting than two-arm trials. We conducted a systematic review to assess the reporting of analyses in reports of
randomized controlled trials (RCTs) with multiple arms.
Methods: The literature in the MEDLINE database was searched for reports of RCTs with multiple arms published in
2009 in the core clinical journals. Two reviewers extracted data using a standardized extraction form.
Results: In total, 298 reports were identified. Descriptions of the baseline characteristics and outcomes per group were
missing in 45 reports (15.1%) and 48 reports (16.1%), respectively. More than half of the articles (n = 171, 57.4%)
reported that a planned global test comparison was used (that is, assessment of the global differences between all
groups), but 67 (39.2%) of these 171 articles did not report details of the planned analysis. Of the 116 articles reporting
a global comparison test, 12 (10.3%) did not report the analysis as planned. In all, 60% of publications (n = 180)
described planned pairwise test comparisons (that is, assessment of the difference between two groups), but 20 of
these 180 articles (11.1%) did not report the pairwise test comparisons. Of the 204 articles reporting pairwise test
comparisons, the comparisons were not planned for 44 (21.6%) of them. Less than half the reports (n = 137; 46%)
provided baseline and outcome data per arm and reported the analysis as planned.
Conclusions: Our findings highlight discrepancies between the planning and reporting of analyses in reports of
multiple-arm trials.
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Randomized controlled trials (RCTs) with multiple arms
are sometimes considered an attractive way of optimiz-
ing resources and simultaneously testing various treat-
ment strategies [1-4]. For instance, multiple-arm trials
can involve increasing doses of an experimental treat-
ment, cumulative combination therapies, or multiple in-
dependent treatments, which can allows testing of the
efficacy of new treatments to be carried out more rapidly
and more directly [5]. Such trials provide more informa-
tion than two-arm trials can provide [6]. Multiple-arm
randomized trials are becoming increasingly common,
with a quarter of randomized trials having more than
two intervention groups [7].* Correspondence: gabriel.baron@htd.aphp.fr
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reproduction in any medium, provided the orHowever, because of the number of arms, such trials can
be more complex in design, data analysis and result
reporting compared with two-arm trials [2,8,9]. Complica-
tions of such trials are directly related to the number of
arms and the number of possible comparisons. For in-
stance, in an RCT with three arms, there are seven theor-
etically possible comparisons [6]. The complications of
such trials include: defining a priori which comparisons
are of primary interest; the possibility of performing global
comparison tests (that is, assessing global differences be-
tween all arms) and/or pairwise comparison tests (that is,
assessing differences of 2 arms), of pooling data for two or
more arms, of reporting selective comparisons (for ex-
ample, only statistically significant comparisons) or post
hoc comparisons (for example, comparisons that were not
planned in the protocol), or of using a multiple compari-
son adjustment procedure for controlling type I error rate,
which influences sample-size calculation and statisticaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the primary outcomes per group for future meta-analyses.
To our knowledge, no systematic review has compared
the planned comparisons (as described in reports) and the
reported comparisons from multiple-arm trials. We aimed
to appraise the reporting of analyses from RCTs with mul-
tiple arms by examining a sample of reports of results of
such trials published in core clinical journals.
Methods
Search strategy
We searched MEDLINE (via PubMed) to identify reports
of RCTs indexed between January and December 2009,
which were published in the core clinical journals defined
by the US National Library of Medicine and the National
Institutes of Health (a subset of 119 widely read journals
published in English, covering all specialties of clinical
medicine and public-health sciences, and including all
major medical journals, which was previously known as the
Abridged Index Medicus and is available at http://www.
nlm.nih.gov/bsd/aim.html). The search strategy used the
following limits: ‘randomized controlled trial’, ‘publication
date from 2009/01/01 to 2009/12/31’ and ‘core clinical
journals’. The date of search was 13 January 2010.
Eligibility criteria and screening process
One of the researchers (GB) screened the titles and ab-
stracts of retrieved articles to identify relevant articles,
then obtained full text of the relevant articles, and assessed
the full text to determine whether the article met the in-
clusion criteria. The help of a second reviewer (IB or EP)
was requested if needed. We considered only articles that
were the first report of the trial results. We excluded sub-
studies of an original publication (for example, follow-up
study, trial extension, ancillary study, post hoc analyses, ex-
ploratory analyses, secondary analyses, reanalysis of a trial,
pooled analyses of trials).
Data collection
A standardized data-extraction form (available from the
corresponding author) was generated from a review of the
literature and a priori discussion. Before data extraction,
the form was tested independently, as a calibration exer-
cise, by two of the authors (GB, EP) on a separate random
set of 20 articles. The ratings were reviewed and any dis-
agreements were resolved by consensus.
Following this, the two reviewers, who were not blinded
to the journal name, authors, author affiliations, or funding
sources, retrieved and extracted data from published arti-
cles. A random sample of 30 articles was reviewed for qual-
ity assurance. Inter-observer agreement in extracting data
was good: the median kappa value for items was 0.68
(range 0.30 to 1.00) (see Additional file 1). In cases of un-
certainty regarding a particular article, items with pooragreement, or items related to the design of the trial, the
data were independently checked by the second reader,
and discrepancies were resolved by discussion.
Data collection
We extracted data related to the general characteristics of
the study: number of randomized groups, study design,
medical area, nature of intervention group(s), number of
centers, total number of randomized participants, rando-
mization design, funding sources, and whether the trial
was registered. We also extracted methodological items:
definition of the study hypothesis (the comparisons
planned in the Methods section), baseline characteristics
and outcomes reported per group (details that would
allow for future meta-analyses), sample-size calculation
reported, sample-size calculation taken into account in the
multiple-arm design (either by a global sample-size calcu-
lation or by an adjustment method used for multiple test-
ing), planning or use of an adjustment method for
statistical comparisons (either for sample-size calculation
or for statistical analysis), and whether the title identified
the trial as a multiple-arm trial. We also systematically
assessed selective reporting by comparing the planned
comparisons (that is, the comparisons reported in the
Methods section) and reported comparisons (the compari-
sons reported in the Results section) for global comparison
tests (which globally assess differences between all groups),
pairwise comparison tests (which compare data between
two groups); and pooled group analyses (which assess
combined data for two or more groups).
Statistical analysis
Because we chose a convenience sample of RCTs, we did
not calculate a required sample size. Our planned ana-
lysis was descriptive, and was stratified by study design
(parallel-arm, factorial, crossover). Categorical variables
are presented as frequencies and percentages, and quan-
titative variables are presented as median (with 10th and
90th percentiles). We specifically investigated compa-
risons that were reported as planned but were not
performed, which could suggest selective reporting. We
also investigated reported comparisons that were not
planned, which could suggest post hoc comparisons. Data
analysis involved use of the software programs SAS (ver-
sion 9.3 for Windows; SAS Institute, Cary, NC, USA)
and R (version 2.15.1; R Foundation for Statistical Com-
puting, Vienna, Austria).
Results
Selection of articles
A flowchart of the selection of articles is shown in
Figure 1. Briefly, the electronic search yielded 2,450 cita-
tions, and after reading the full text, we selected 298 re-
ports published in 68 journals (see Additional file 2). In
Figure 1 Study screening process.
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journals and 250 (83.9%) in specialized medical journals.
Characteristics of multiple-arm trials
The characteristics of the trials are shown in Table 1. Of
the 1690 RCTs assessed, the proportion of multiple-arm
trials was 17.6% (n = 298; 95% confidence interval 15.8 to
19.5), with 221 (74.2%) having a parallel-group design, 37 a
factorial design (12.4%), and 40 (13.4%) a crossover design.
The most common intervention was a drug (n = 192,
64.4%), and trials were mostly designed to show superiority
(n = 260, 87.3%).
The number of arms varied from 3 to 16, being 3 in 172
reports (57.7%), 4 in 84 reports (28.2%) and more than 4 in
42 reports (14.1%). The median number of participants per
arm was 39 (10th to 90th percentile 7 to 228). Overall, 80
reports described a single-center trial (26.9%), and 141 a
multicenter trial (47.3%). The source of funding was de-
scribed as solely or partially industry in 101 reports (33.9%)
and public in 118 (39.6%). Characteristics were similar
across the three trial-design types (Table 1), although some
characteristics reflected the specificity of each subgroup
(for example, the number of arms was greater for factorialdesigns, and the number of randomized patients was larger
for parallel trials than for crossover trials).
Of the trials with a parallel-group design, excluding
those with a factorial design (n = 221, 74.2%), 82 (37.1%)
were dose–response trials (use of multiple doses of the
same treatment) and 139 (62.9%) compared different
treatments. Trials with three arms (n = 172) included sev-
eral types of interventions and control arms (Figure 2).
Reporting
Table 2 provides information on the reporting of the re-
sults of multiple-arm trials.
Reporting of baseline characteristics and outcomes
The description of baseline characteristics and outcomes
per group were missing in 45 (15.1%) and 48 (16.1%), re-
spectively, of the reports investigated. Of the 57 publications
describing pooled analyses (19.1%), 17 (28.1%) did not pro-
vide results for each randomized group.
Planned and reported comparisons
We identified 60 articles (20.1%) that did not define the
study hypothesis. More than half of the articles (n = 171,
Table 1 Characteristics of randomized controlled trials with multiple arms by trial design
All trials, n = 298 Trial design
Parallel group, n = 221 Parallel group with factorial, n = 37 Crossovera, n = 40
No. of study groups
3 172 (57.7) 152 (68.8) 0 (0.0) 20 (50.0)
4 84 (28.2) 39 (17.7) 34 (91.9) 11 (27.5)
> 4 42 (14.1) 30 (13.6) 3 (8.1) 9 (22.5)
Common specialties
Anesthesia 54 (18.1) 47 (21.3) 3 (8.1) 4 (10.0
Endocrinology 32 (10.7) 20 (9.1) 5 (13.5) 7 (17.5)
Cardiology 31 (10.4) 25 (11.3) 6 (16.2) 0 (0.0)
Infectious disease 22 (7.4) 20 (9.1) 1 (2.7) 1 (2.5)
Rheumatology 19 (6.4) 18 (8.1) 1 (2.7) 0 (0.0)
Intervention
Drug 192 (64.4) 148 (68.0) 22 (59.5) 22 (55.0)
Surgery or procedure 17 (5.7) 12 (5.4) 1 (2.7) 4 (10.0)
Counseling or lifestyle interventions 47 (15.8) 33 (14.9) 10 (27.0) 4 (10.0)
Equipment or device 26 (8.7) 19 (8.6) 2 (5.4) 5 (12.5)
Others 16 (6.7) 5 (1.7) 2 (0.7) 9 (3.0)
Study centers
Single 80 (26.9) 54 (24.4) 8 (21.6) 18 (5.0)
Multiple 141 (47.3) 110 (49.8) 24 (64.9) 7 (13.5)
Not reported 77 (25.8) 57 (25.8) 5 (13.5) 15 (37.5)
No. of randomized patients per:
Trial, median
(10th to 90th percentile)
136 (25 to 800) 148 (45 to 650) 468 (120 to 1653) 21 (12 to 61)
Arm, median
(10th to 90th percentile)
39 (7 to 228) 43 (12 to 204) 117 (30 to 413) 5 (3 to 16)
Cluster trial 13 (4.4) 8 (3.6) 3 (8.1) 2 (5.0)
Trial type
To show superiority 260 (87.3) 195 (88.8) 33 (89.2) 32 (80.0)
To show non-inferiority or
equivalence
12 (4.0) 8 (3.6) 4 (10.8) 0 (0.0)
Pharmacokinetic/pharmacodynamic
objective
26 (8.7) 18 (8.1) 0 (0.0) 8 (20.0)
Randomization design
Balanced 263 (88.3) 190 (86.0) 33 (89.2) 40 (100.0)
Unbalanced 30 (10.1) 28 (12.7) 2 (5.4) 0 (0.0)
Unclear 5 (1.7) 3 (1.3) 2 (5.4) 0 (0.0)
Funding source
Solely or partially industry 101 (33.9) 77 (34.8) 11 (29.7) 13 (32.5)
Public 118 (39.6) 87 (39.4) 14 (37.8) 17 (42.5)
None 8 (2.7) 6 (2.7) 1 (2.7) 1 (2.5)
Unknown 71 (23.8) 51 (23.1) 11 (29.8) 9 (22.5.0)
Trial registration reported 144 (48.3) 109 (49.3) 27 (73.0) 8 (20.0)
a There were 4 of the 40 crossover trials with a factorial design.
Baron et al. BMC Medicine 2013, 11:84 Page 4 of 7
http://www.biomedcentral.com/1741-7015/11/84
Figure 2 Nature of intervention arms in three-arm randomized controlled trials.
Table 2 Reporting of randomized controlled trials with multiple arms by trial design
All trials, n = 298 Trial design
Parallel group,
n = 221
Parallel group with factorial,
n = 37
Crossover
(n = 40)
Reporting item
Study hypothesis defined 238 (79.9) 173 (78.3) 33 (89.1) 32 (80.0)
Baseline characteristics available per group 253 (84.9) 196 (88.7) 28 (75.7) 29 (72.5)
Results on outcomes available per group 250 (83.9) 190 (85.0) 27 (73.0) 33 (82.5)
Global test comparison
Planned 171 (57.4) 127 (57.5) 23 (62.2) 21 (52.5)
Reported 116 (38.9) 84 (38.0) 18 (48.7) 14 (35.0)
Pairwise test comparisons
Planned 180 (60.4) 144 (65.2) 11 (29.7) 25 (62.5)
Reported 204 (68.5) 162 (73.3) 15 (40.5) 27 (67.5)
Sample-size calculation
Reported 210 (70.5) 159 (72.0) 30 (81.1) 21 (52.5)
Taken into account in the multi-arm design 41/210 (19.5) 35/159 (22.0) 5/30 (16.7) 1/21 (4.8)
Adjustment method used to control type I error
due to multiple-arm designa
118 (39.6) 89 (40.3) 10 (27.0) 19 (47.50)
Title identified the study as a multiple-arm trial 130 (43.6) 101 (45.7) 19 (51.4) 10 (25.0)
a For sample-size calculation or for statistical analysis.
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but 67 (39.2%) did not report the results of the planned
analysis. Of the 116 articles reporting a global comparison
test, the test was not reported as planned for 12 (10.3%). In
all, 60% of publications (n = 180) reported that a pairwise
comparison test was planned, but 20 of these (11.1%) did
not report a pairwise test comparison. Of the 204 articles
reporting pairwise test comparisons, these comparisons
were not reported as planned for 44 (21.6%). Less than half
of the reports (46%, n = 137) provided baseline and out-
come data per group or reported the analysis (global and/
or pairwise comparison) as planned.Other elements of reporting
Overall, 70.5% of reports (n = 210) reported a sample-
size calculation. The multiple-arm design was taken into
account in the sample-size calculation for 41 of 210 re-
ports (19.5%). Of the total of 298 reports, 118 (39.6%)
described an adjustment method for multiple statistical
comparisons, and 9 (5.0%) of the remaining 180 articles
explained why no adjustment was used. Less than half of
the trials reports identified the multiple arms in the title
(n = 130, 43.6%). For all trials, the reporting of characteris-
tics seemed to be generally poorer for crossover than
parallel-group trials, particularly for items concerning
sample size (Table 2).Discussion
Our findings highlight the inadequate reporting of base-
line characteristics and outcomes for arms in multiple-
arm RCTs, and the discrepancies between planned and
reported comparisons. Moreover, such trials generally had
relatively small sample sizes, and showed great variability
in the types of intervention and the control arms used.
Multiple-treatment arms are possible sources of multi-
plicity in an RCT [6,10]. This multiplicity is related to
the possibility of performing several pairwise tests to de-
termine the most effective arm. In such a setting, the ob-
jectives of the trial must be clear to ensure that these
objectives (and only these) are correctly designed and
analyzed (for example, global test comparison or not,
and which pairwise test comparisons are planned). In
20% of the reports we analyzed, the study hypothesis
was not described, which suggests selective reporting.
Moreover, bias may be introduced if the decisions on
data analysis are driven by the data [11]. For instance,
groups receiving different doses of the same intervention
could be combined after the data are examined, or only
statistically significant pairwise comparisons could be
reported. The number of possible comparisons increases
greatly in trials with more than three arms, which sug-
gests increased risk of selective reporting. Our results
are likely have underestimated any selective outcomereporting bias because we assessed articles and not pro-
tocols [12].
Moreover, in our study, some reports did not describe
baseline or outcome data for each group (occurred in
more than 15% of reports for each scenario). These results
are consistent with previous work [13], and are important
because reporting data per group is a necessary condition
for future meta-analyses.
One of the other methodological difficulties in multiple-
arm RCTs concerns the calculation of the sample size, and
particularly the necessity for adequate power. Many ran-
domized trials with two parallel arms exhibit inadequate
power for revealing differences [14], and sample-size cal-
culation is poorly reported in articles of trials and can be
inaccurate [15]. With multiple-arm trials, problems with
power and calculation are enhanced, particularly because
sample-size calculation depends on the main objective(s)
of the trial and thus on the underlying hypotheses that will
be tested [1]: whether a global test should be performed or
not, and whether (and how many) pairwise comparisons
were planned, with statistical adjustment or not.
The question of adjusting for control type I error in
multiple-arm trials is a subject of debate [2,3,6,16-18].
Controlling for type I error is not needed when several ex-
perimental arms are compared with the control or the
standard arms [3], but is necessary when adjusting for post
hoc comparisons or when the tested hypotheses cannot be
prioritized [18]. Reasons for using adjustment or not are
often subjective, and should be justified [18].
Our study has several limitations. First, we assessed re-
ports of RCTs and not protocols. This point is particularly
important for assessing planned comparisons. We did not
assess protocols because of the difficulties in obtaining ac-
cess to trial protocols [19]. Second, the methods may have
been pre-specified but not reported in the articles [20,21].
Third, our results are limited to the core clinical journals
defined by the National Library of Medicine, so our find-
ings may not be applicable to journals outside this sample.
We chose the core clinical journals because they cover all
clinical and public-health areas and all major medical
journals. The methodological quality of reports in other
journals is unlikely to be better than in these journals.
Conclusion
The CONSORT (Consolidated Standards of Reporting
Trials) group is developing recommendations to help im-
prove the reporting of multiple-arm trials [22,23]. Com-
pared with two-arm RCTs, multiple-arm trials are more
complex to design and require more complex analysis,
and the results are more complex to report. The design
and objectives of the trials have direct consequences for
the conduct, analysis of results (for example, planned
comparisons, sample-size calculation, adjustment during
analysis) and reporting. The specific characteristics of
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in addition to the usual requirements for reporting the re-
sults of RCTs (such as randomization, concealment, and
blinding), pose a supplementary challenge for authors
reporting the results of multiple-arm trials.
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